Will Annovis Bio stock go up?

According to Danelfin AI, Annovis Bio has today an AI Score of 5/10 (Hold rating), because its probability of beating the market in 3 months (51.57%) is +0.75% vs. the average probability (50.82%) of all US-listed stocks.

What is the target price for Annovis Bio stock?

The Annovis Bio target price is $1.94 (1Y), according to the average price target offered by analysts.

Is it a good time to buy, sell, or hold Annovis Bio stock right now?

Annovis Bio has today a Hold rating (AI Score 5/10), according to Danelfin AI. Its probability of beating the market in 3 months (51.57%) is +0.75% vs. the average probability (50.82%) of all US-listed stocks, based on our AI-powered analysis. You can find more details on whether Annovis Bio stock is a good buy .

Is Annovis Bio undervalued right now?

Based on analysts, the average price target downside for Annovis Bio is 0.00% (1Y). According to Danelfin AI, Annovis Bio has today an AI Score of 5/10 (Hold Rating).

What was the price range of Annovis Bio stock over the past 12 months?

The Annovis Bio stock price range over the past 12 months has been $1.59 - $5.1.

What is going on with Annovis Bio stock in the last 3 months?

The Annovis Bio stock performance in the last quarter has been -8.49%.

Does Annovis Bio offer dividend payments?

No, Annovis Bio does not currently pay dividends.

What is the current market capitalization of Annovis Bio?

Annovis Bio's market cap is $82.11M, as of 2026-07-03 08:00.

Annovis Bio Inc (ANVS) AI Stock Analysis

Advanced Chart

Custom range

Jul 3, 2025

→

Jul 3, 2026

Custom range

Jul 3, 2025

→

Jul 3, 2026

ANVS AI-Powered Stock Analysis

AI Score Explanation

AI Score

Hold

Fundamental
Technical
Sentiment
Low Risk

According to Danelfin’s proprietary AI model, Annovis Bio Inc today receives an AI Score of 5/10, which translates to a Hold rating. The stock has a 52% probability of outperforming the market in the next 3 months, which is 1% higher than the average probability of any stock (51%). Key positive contributors include Operating Cash Flow (Qtr Discrete) (impact: +0.60%), which is in the bottom 20% but still boosts the probability, and Chart Pattern (252d) (impact: +0.35%), which positively influences the outlook. On the negative side, the Fear & Greed Index (CNN) (impact: -0.26%) and Fundamentals Impact (Long Tail) (impact: -0.15%) detract from the probability, along with Alpha 6M (impact: -0.15%, bottom 10%) and Tangible Shareholders' Equity (impact: -0.12%, bottom 30%). Notable data points include a Performance (YTD) of -43.93% (bottom 20%), which paradoxically adds to the probability, and an Alpha 1Y of -37.33% (bottom 40%), also a positive contributor. However, Alpha 6M at -52.35% (bottom 10%) is a strong detractor, reflecting recent underperformance. The ATR (14d Volatility) is 0.13 (bottom 20%), indicating low volatility, which positively influences the model. Overall, the stock's probability is only slightly above average, with mixed signals from fundamentals and technicals, resulting in a neutral Hold rating.

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

Earnings Quality+0.60%
Stability and reliability of reported earnings
Momentum+0.54%
Direction and strength of recent price movements
Volatility+0.20%
How much the stock price tends to fluctuate
Growth+0.09%
Expected pace of revenue and earnings expansion
Size & Liquidity+0.08%
Company size and trading liquidity
Profitability+0.08%
Profitability and operating efficiency metrics

Valuation-0.43%
How the stock is priced relative to its fundamentals
Sentiment-0.29%
How analysts and the market view the stock
Financial Strength-0.11%
Balance sheet strength and financial resilience

ANVS probability advantage of beating the market (3M):

+0.75%

AI Score

Hold

Annovis Bio (ANVS) has an AI Score of 5/10 (Hold) because, according to an overall analysis, it has a probability advantage of +0.75% of beating the market (S&P500) in the next 3 months. This advantage is calculated as the difference between the average probability of any US-listed stock (50.82%) and the probability of ANVS (51.57%) of outperforming the market in the next 3 months, as determined by Danelfin AI’s comprehensive analysis.

Average probability of any US-listed stock of beating the market (3M)50.82%
ANVS probability advantage of beating the market (3M)+0.75%
ANVS probability of beating the market (3M)51.57%

ANVS probability advantage of beating the market (3M): +0.75%

The AI-powered overall analysis of Annovis Bio (ANVS) is based on the 27 fundamental, technical, and sentiment features that had the greatest impact on stock performance during the last 12 months (alpha signals). These alpha signals explain the probability advantage of ANVS:

Type	Alpha Signal	Current Value	Value Decile Position	Probability Advantage Impact (3M)
Fundamental	Operating Cash Flow (Qtr Discrete)	-9.01		+0.60%
Technical	Chart Pattern (252d)	figure_94	N/A	+0.35%
Sentiment	Fear & Greed Index (CNN)	31	N/A	-0.26%
Technical	Performance (YTD)	-0.44%		+0.22%
Technical	Alpha 1Y	-0.37%		+0.19%
Sentiment	Sentiment Impact (Long Tail)	-	N/A	+0.17%
Fundamental	Fundamentals Impact (Long Tail)	-	N/A	-0.15%
Technical	Alpha 6M	-0.52%	N/A	-0.15%
Technical	ATR (14d Volatility)	0.13		+0.12%
Fundamental	Tangible Shareholders' Equity	3.13		-0.12%
Fundamental	Upgrade to unlock			-0.11%
Sentiment	Upgrade to unlock			-0.11%
Technical	Upgrade to unlock			-0.11%
Technical	Upgrade to unlock			+0.11%
Sentiment	Upgrade to unlock			+0.11%

Rest of Alpha Signals: -0.10%

ANVS probability advantage of beating the market (3M)Total:+0.75%
ANVS AI Score

Significant changes Vs previous day

ANVS Trading Parameters

These suggested trading parameters for a 3-month horizon help improve risk management and decision-making.

Entry:$1.94
Horizon: 3 months
Stop Loss:$XXXXXPro (XXXXXPro) or AI Score < 4/10
Take Profit:$XXXXXPro (XXXXX
Pro
) or AI Score < 4/10

ANVS Proven Hold Signal & Price Forecast

This is the price chart for ANVS from January 2, 2026 until today. The chart indicates, in yellow, the 32 days when the stock received a Hold rating (hold signals, AI Score 4 to 6).

Forecast: In the section below, the central dotted line represents the most expected path, while the shaded area indicates the anticipated price range. This is based on previous Hold signals with a 90% confidence level.

Full Track Record

Unlock AI-powered forecast

Closing price (USD)
Hold signals

Forecast:

1 Month
3 Months
6 Months
1 Year

ANVS Average Past Performance & Win Rate

Three months after its 887 Hold signals since July 2026, ANVS had an average performance of xxxxxxx and a xxxxxx Win rate (positive performance).

887 Past ANVS Hold Signals	1 Month Later	3 Months Later	6 Months Later	1 Year Later
Average Performance				+192.19%
Average Alpha				+175.57%
Win Rate (% Positive Perf.)				37.12%
% Positive Alpha				33.66%

ANVS Frequently Asked Questions

Will Annovis Bio stock go up?
According to Danelfin AI, Annovis Bio has today an AI Score of 5/10 (Hold rating), because its probability of beating the market in 3 months (51.57%) is +0.75% vs. the average probability (50.82%) of all US-listed stocks.
What is the target price for Annovis Bio stock?
Is it a good time to buy, sell, or hold Annovis Bio stock right now?
Is Annovis Bio undervalued right now?
What was the price range of Annovis Bio stock over the past 12 months?
What is going on with Annovis Bio stock in the last 3 months?
Does Annovis Bio offer dividend payments?
What is the current market capitalization of Annovis Bio?

Annovis Bio Inc Company Profile

Specializing in the development of drugs for neurodegenerative conditions, Annovis Bio Inc. works within the realm of clinical stage drug platforms. Buntanetap, their frontrunning product candidate has entered the Phase 3 clinical trials and is being examined for its potential role in treating Alzheimer's disease (AD), Parkinson's disease, as well as other chronic neurodegenerative disorders. Further in line, they've introduced ANVS405 - a drug positioned for safeguarding the brain following traumatic events or a stroke; additionally, ANVS301 is on their docket too which is in the first phase of clinical trials designed to enhance cognitive functions during advanced stages of AD and dementia. With inception occurring in 2008, today Annovis Bio's foundational groundwork stands robust within Berwyn, Pennsylvania.

Sector:
Country:United States
Industry:
Address:101 Lindenwood Drive, Suite 225, Malvern
Employees:8
Website:annovisbio.com

Pros

Large unmet medical need in neurodegenerative diseases

Proprietary small molecule drug development platform

Potential for broad applicability across multiple indications

High pricing power for breakthrough therapies

Intellectual property protection for novel compounds

Cons

High clinical trial failure rates in CNS disorders

Intense capital requirements for drug development

Long development timelines to market approval

Regulatory approval uncertainty for novel mechanisms

Competition from larger pharmaceutical companies

Company	AI Score	Compare
AVXLAnavex Life Sciences Corp
BIVIBioVie Inc
ABVCABVC Biopharma Inc
ANABAnaptysBio Inc
SUPNSupernus Pharmaceuticals Inc

Company	AI Score	Compare
AVXLAnavex Life Sciences Corp
BIVIBioVie Inc
ABVCABVC Biopharma Inc
ANABAnaptysBio Inc
SUPNSupernus Pharmaceuticals Inc

ANVS Stock AI Analysis

Annovis Bio Inc

ANVS Stock AI Analysis

Annovis Bio Inc

ANVS AI-Powered Stock Analysis

AI Score Explanation

AI Score Explanation

Generating AI Score explanation

AI Score Alpha Factors

Alpha Signals: What Drives the AI Score

ANVS probability advantage of beating the market (3M): +0.75%

ANVS Trading Parameters

ANVS Proven Hold Signal & Price Forecast

ANVS Average Past Performance & Win Rate

ANVS Frequently Asked Questions

Will Annovis Bio stock go up?

What is the target price for Annovis Bio stock?

Is it a good time to buy, sell, or hold Annovis Bio stock right now?

Is Annovis Bio undervalued right now?

What was the price range of Annovis Bio stock over the past 12 months?

What is going on with Annovis Bio stock in the last 3 months?

Does Annovis Bio offer dividend payments?

What is the current market capitalization of Annovis Bio?

Annovis Bio Inc Company Profile

Pros

Cons

Pros

Cons

ANVS Company Profile Summary

ANVS Related Investment Themes

ANVS Related Stocks

ANVS Top 10 Industry Stocks

Biotechnology

ANVS Top 10 Sector Stocks

Health Care

ANVS Stock AI Analysis

Annovis Bio Inc

NEW YORK STOCK EXCHANGE, INC.

Will Annovis Bio stock go up?

What is the target price for Annovis Bio stock?

Is it a good time to buy, sell, or hold Annovis Bio stock right now?

Is Annovis Bio undervalued right now?

What was the price range of Annovis Bio stock over the past 12 months?

What is going on with Annovis Bio stock in the last 3 months?

Does Annovis Bio offer dividend payments?

What is the current market capitalization of Annovis Bio?

ANVS Proven Hold Signal & Price Forecast

NEW YORK STOCK EXCHANGE, INC.

Pros

Cons

AI Score Explanation